a
Biological evaluation of in silico repositioned FDA-approved drugs as potential inhibitors of Porphyromonas gingivalis gingipain K, a causative agent for Alzheimer’s disease
IMU Internal Research Grant | 20 May 2024 - 30 Sep 2024
a
2D ligand-based similarity searching and structure-based virtual screening for identification of potential Porphyromonas gingivalis peptidylarginine deiminase inhibitors as rheumatoid arthritis pharmacotherapy
IMU Internal Research Grant | 08 Apr 2024 - 07 Feb 2025
a
Evaluation of effectiveness of 3-D virtual molecules for teaching and learning of chemistry in foundation in science and pharmaceutical chemistry programmes
IMU Internal Research Grant | 18 Mar 2024 - 31 Dec 2024
a
Computational drug repurposing study of Porphyromonas gingivalis peptidylarginine deiminase inhibitors with FDA-approved drugs as potential pharmacotherapy for rheumatoid arthritis: an extended investigation
IMU Internal Research Grant | 04 Sep 2023 - 29 Jun 2024
a
In silico repurposing of FDA-approved drugs as inhibitors of Porphyromonas gingivalis gingipain K, a causative agent for Alzheimer’s disease
IMU Internal Research Grant | 01 Jun 2023 - 31 Aug 2023
a
In silico pharmacokinetic and molecular docking studies of labdane diterpenes of Alpinia genus against butyrylcholinesterase, a therapeutic target for Alzheimer’s disease
IMU Internal Research Grant | 01 Jul 2022 - 02 May 2023
a
In silico repositioning of FDA-approved drugs as inhibitors of Porphyromonas gingivalis peptidylarginine deiminase and gingipain R, the putative causal agents of rheumatoid arthritis
IMU Internal Research Grant | 01 Jul 2022 - 30 Sep 2022
a
In silico repurposing of FDA-approved drugs as inhibitors of Porphyromonas gingivalis peptidylarginine deiminase and gingipain R, the putative causal agents of rheumatoid arthritis
IMU Internal Research Grant | 21 Mar 2022 - 23 May 2022
a
Bacterial photoinactivation potency of ruthenium photosensitizers
IMU Internal Research Grant | 01 Dec 2021 - 31 Jul 2022
a
Repositioning of FDA-approved drugs as inhibitors of Porphyromonas gingivalis gingipain K, a a causative agent for Alzheimer’s disease: in silico and biological evaluation
IMU Internal Research Grant | 03 May 2021 - 30 Nov 2021
a
Repositioning of FDA-approved drugs as inhibitors of Porphyromonas gingivalis gingipain R, a putative causal agent of rheumatoid arthritis: in silico and biological evaluation
IMU Internal Research Grant | 02 Nov 2020 - 30 Jun 2021
a
In silico repositioning of FDA-approved drugs as inhibitors of Porphyromonas gingivalis peptidylarginine deiminase, a putative causal agent of rheumatoid arthritis
External Grant from Tunku Abdul Rahman University College | 01 Sep 2019 - 01 Mar 2021
a
Literature review: Multi-target approaches in malaria drug discovery
IMU Internal Research Grant | 03 Dec 2018 - 28 Feb 2019
a
In silico and in vitro antibacterial evaluation of Schiff base ligands and their metal complexes
IMU Internal Research Grant | 05 Sep 2018 - 12 May 2021
a
Synthesis of Novel Bis (Indolymethyl) Carbazoles
IMU Internal Research Grant | 01 Jul 2018 - 01 Nov 2018
a
Synthesis, Characterisation and Antimicrobial (In vitro and In Silico) Evaluation of Schiff Base Ligands and their Metal Complexes
IMU Internal Research Grant | 01 Jun 2018 - 01 Dec 2018
a
Instructional Briefing Video: An Approach to Enhance Students Self-Directed Learning for Laboratory Practical Sessions
IMU Internal Research Grant | 01 Sep 2016 - 01 Dec 2017
a
Effect of some organic and inorganic proteasome inhibitors on the growth of selected bacteria
IMU Internal Research Grant | 01 Dec 2015 - 29 Feb 2016
a
Bicyclic scaffold as versatile template for the design of human adenosine receptor antagonists: Comparison of pharmacophore elucidation at the A2A and A3 adenosine receptor.
IMU Internal Research Grant | 01 May 2015 - 31 Oct 2015
a
Novel Cu (II) Schiff Base Complex Combination with Polymyxin B/Phenylalanine-Arginine β-Naphthylamide Against Various Bacterial Strains
INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS | 2022
a
Current Pharmacotherapy and Multi-Target Approaches for Alzheimer’s Disease
PHARMACEUTICALS | 2022
a
Inhibition of Porphyromonas gingivalis peptidyl arginine deiminase, a virulence factor, by antioxidant-rich Cratoxylum cochinchinense: In vitro and in silico evaluation
SAUDI JOURNAL OF BIOLOGICAL SCIENCES | 2022
a
Implications of Porphyromonas gingivalis peptidyl arginine deiminase and gingipain R in human health and diseases
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY | 2022
a
Current progress in antimalarial pharmacotherapy and multi-target drug discovery
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2020
a
Design, synthesis and evaluation of new indolylpyrimidylpiperazines for gastrointestinal cancer therapy
MOLECULES | 2019
a
Design, Synthesis and Characterisation of Novel Phenothiazine‐Based Triazolopyridine Derivatives: Evaluation of Anti‐Breast Cancer Activity on Human Breast Carcinoma
CHEMISTRYSELECT | 2019
a
The current status of pharmacotherapy for the treatment of Parkinson’s disease: transition from single-target to multitarget therapy
DRUG DISCOVERY TODAY | 2019
a
Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment
PLOS ONE | 2018
a
Pharmacological relationships and ligand discovery of G protein-coupled receptors revealed by simultaneous ligand and receptor clustering
JOURNAL OF MOLECULAR GRAPHICS AND MODELLING | 2017
a
A3 adenosine receptor ligands in the treatment of inflammation and cancer
PHARMACOLOGY-RESEARCH, SAFETY TESTING AND REGULATION | 2016
a
A facile and novel synthesis of N2-, C6-substituted pyrazolo [3, 4-d] pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2015
a
Discovery of simplified N2-substituted pyrazolo [3, 4-d] pyrimidine derivatives as novel adenosine receptor antagonists: Efficient synthetic approaches, biological evaluations and molecular docking studies
BIOORGANIC & MEDICINAL CHEMISTRY | 2014
a
Organoruthenium antagonists of human A3 adenosine receptors
CHEMISTRY"A EUROPEAN JOURNAL | 2013
a
The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches
MEDICINAL RESEARCH REVIEWS | 2013
a
Does the combination of optimal substitutions at the C2-, N5-and N8-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A3 adenosine receptors?
BIOORGANIC & MEDICINAL CHEMISTRY | 2011
a
Biomedical applications I: Delivery of drugs
N/A | 2011
a
Pharmacophore elucidation for a new series of 2-aryl-pyrazolo-triazolo-pyrimidines as potent human A3 adenosine receptor antagonists
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011
a
Pyrazolo derivatives as potent adenosine receptor antagonists: an overview on the structure-activity relationships
INTERNATIONAL JOURNAL OF MEDICINAL CHEMISTRY | 2011
a
Synthesis and biological evaluation of a new series of 1, 2, 4-triazolo [1, 5-a]-1, 3, 5-triazines as human A2A adenosine receptor antagonists with improved water solubility
JOURNAL OF MEDICINAL CHEMISTRY | 2011
a
The Significance of 2-Furyl Ring Substitution with a 2-(para-substituted) Aryl Group in a New Series of Pyrazolo-triazolo-pyrimidines as Potent and Highly Selective hA3 Adenosine Receptors Antagonists: New Insights into Structure− Affinity Relationship and Receptor− Antagonist Recognition
JOURNAL OF MEDICINAL CHEMISTRY | 2010
a
In silico pharmacokinetic and molecular docking studies of labdane diterpenes of Alpinia genus against butyrylcholinesterase, a therapeutic target for Alzheimer’s disease
Monash INITIATE 2023, Monash International Health Science and Technology Conference | 25 Oct 2023
a
Use of 3-D virtual molecules for teaching and learning of stereochemistry in undergraduate programmes
16th International Medical Education Conference 2023 | 13 Oct 2023
a
Membrane-targeting peptides enhancing uptake of ruthenium(II) polypyridyl photosensitisers into clinically relevant bacteria
MyCRS Young Scientist Symposium 2023 | 17 Aug 2023
a
Repositioning of FDA-approved drugs as inhibitors of Porphyromonas gingivalis gingipain K, a causative agent for Alzheimer’s disease: in silico and biological evaluation
Monash INITIATE 2022 | 27 Sep 2022
a
Repositioning of FDA-approved drugs as inhibitors of Porphyromonas gingivalis gingipain K, a causative agent for Alzheimer’s disease: in silico and biological evaluation
International Postgraduate Conference on Pharmaceutical Sciences (IPoPS) | 21 Jun 2022
a
Repurposing of FDA-approved drugs as inhibitors of Porphyromonas gingivalis gingipain R, a causal agent of rheumatoid arthritis: in silico and biological studies
Royal Society of Chemistry International Accreditation Celebration Event | 12 Oct 2021
a
Repositioning of FDA-approved drugs as inhibitors of Porphyromonas gingivalis gingipain R, a putative causal agent of rheumatoid arthritis: in silico and biological evaluation
Virtual International Research Network Initiative (IRNI) and International Postgraduate Conference on Pharmaceutical Sciences (IPoPS) | 28 Sep 2021
a
Rational design of new ligands as human adenosine receptor antagonists: transition from tricyclic to bicyclic scaffold-based derivatives
8th Edition of International Conference on Chemistry Education and Research | 27 Aug 2018
a
In silico pharmacophore elucidation for bicyclic antagonists of human A3 adenosine receptors and its comparison with A2A adenosine receptor bicyclic antagonists
12th Malaysian Pharmaceutical Society - Pharmacy Scientific Conference | 13 Nov 2015
a
In silico pharmacophore elucidation for bicyclic antagonists of human A2A adenosine receptors and its comparison with A3 adenosine receptor bicyclic antagonists
12th Malaysian Pharmaceutical Society - Pharmacy Scientific Conference | 13 Nov 2015
a
Alkylamino-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines. Influence of the substituent on the affinity at the adenosine receptor subtypes
Congresso Nazionale della Società Chimcia Italiana XXIV | 11 Sep 2011
a
1, 2, 4-Triazolo [1, 5-a]-1, 3, 5-triazine nucleus: a possible template for adenosine receptor subtypes.
Nuove Prospettive in Chimica Farmaceutica V | 01 Mar 2011
a
Structural investigations on a novel class of 1,2,4-triazolo[1,5-c]pyrimidines as adenosine receptor antagonists
Nuove Prospettive in Chimica Farmaceutica V | 01 Mar 2011
a
The pyrazolo-triazolo-pyrimidine scaffold as a versatile platform to design potent and highly selective hA3 adenosine receptor’s antagonists
8th Annual Congress of International Drug Discovery Science and Technology | 23 Oct 2010
a
A new series of 2-aryl-pyrazolo-triazolo-pyrimidines as potent human A3 adenosine receptor antagonists: QSAR analysis and COMFA-guided modeling of antagonist binding site through a human A3 ‘hybrid’ homology model
18th European Symposium on Quantitative Structure-Activity Relationships | 19 Sep 2010
a
The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA3 adenosine receptor’s antagonists: New insights into structure-affinity relationship and receptor-antagonist recognition
Nuove Prospettive in Chimica Farmaceutica IV | 06 May 2010
a
The pyrazolo-trizolo-pyrimidine scaffold as a versatile platform to design potent and highly selective hA3 adenosine receptor antagonists: the role of 2-furyl ring substitution demystified through analysis on a novel series of 2-(para-substituted) aryl analogs
Nuove Prospettive in Chimica Farmaceutica IV | 06 May 2010
a
Synthesis, characterization and evaluation of new human adenosine receptors’ antagonists
Bandung International Conference on Medicinal Chemistry | 06 Aug 2009
a
Synthesis, characterization and evaluation of new adenosine receptors’ antagonists
European School of Medicinal Chemistry | 06 Jul 2008
a
Synthesis, characterization and evaluation of new adenosine receptors’ antagonists
PharmSci@Asia Symposium | 01 Jun 2008
a
Synthesis, characterization and evaluation of new adenosine receptors’ antagonists
19th Singapore Pharmacy Congress | 19 Oct 2007
a
Società chimica Italiana (2012). Structural Investigations on a Novel Class of [1, 2, 4] Triazolo [1, 5-c] pyrimidines as Adenosine Receptor Antagonists.
a
Società chimica italiana (2011). 5-Alkylamino-pyrazolo [4, 3-e] 1, 2, 4-triazolo [1, 5-c] pyrimidines. Influence of the Substituent on the Affinity at the Adenosine Receptor Subtypes
a
Nieh Zee Ernn Ryan | Undergraduate | 18 Mar 2024 - 31 Dec 2024
Thesis: Evaluation of effectiveness of 3-D virtual molecules for teaching and learning of chemistry in foundation in science and pharmaceutical chemistry programmes
a
Lee Peak Ngan | Master (Mixed Mode) | 04 Sep 2023 - 29 Jun 2024
Thesis: Computational drug repurposing study of Porphyromonas gingivalis peptidylarginine deiminase inhibitors with FDA-approved drugs as potential pharmacotherapy for rheumatoid arthritis: an extended investigation
a
Ong Wei Quan, Muhamad Zakwan Hafiq bin Abdul Razak | Undergraduate | 01 Jun 2023 - 31 Aug 2023
Thesis: In silico repurposing of FDA-approved drugs as inhibitors of Porphyromonas gingivalis gingipain K, a causative agent for Alzheimer’s disease
a
Leong How Wan | Master (Mixed Mode) | 01 Jul 2022 - 02 May 2023
Thesis: In silico pharmacokinetic and molecular docking studies of labdane diterpenes of Alpinia genus against butyrylcholinesterase, a therapeutic target for Alzheimer’s disease
a
Lai Weng Yeen, Wo Weeng Yue | Undergraduate | 01 Jul 2022 - 30 Sep 2022
Thesis: In silico repositioning of FDA-approved drugs as inhibitors of Porphyromonas gingivalis peptidylarginine deiminase and gingipain R, the putative causal agents of rheumatoid arthritis
a
Yap Soong Zhi, Ang Kin Loon | Undergraduate | 21 Mar 2022 - 23 May 2022
Thesis: In silico repurposing of FDA-approved drugs as inhibitors of Porphyromonas gingivalis peptidylarginine deiminase and gingipain R, the putative causal agents of rheumatoid arthritis
a
Mohamedali Elhag Mohamed Ahmed, Bong Wan Qing | Undergraduate | 01 Dec 2021 - 31 Jul 2022
Thesis: Bacterial photoinactivation potency of ruthenium photosensitizers
a
Lai Jia Hui | Master (Mixed Mode) | 03 May 2021 - 30 Nov 2021
Thesis: Repositioning of FDA-approved drugs as inhibitors of Porphyromonas gingivalis gingipain K, a a causative agent for Alzheimer’s disease: in silico and biological evaluation
a
Samantha Valerie Anak Unting | Master (Mixed Mode) | 02 Nov 2020 - 30 Jun 2021
Thesis: Repositioning of FDA-approved drugs as inhibitors of Porphyromonas gingivalis gingipain R, a putative causal agent of rheumatoid arthritis: in silico and biological evaluation
a
Gan Wei Khang | Master (Mixed Mode) | 01 Dec 2019 - 01 Dec 2020
Thesis: In silico and in vitro antibacterial evaluation of Schiff base ligands and their metal complexes
a
Chow Yoke Chan | Master (Research) | 01 Sep 2019 - 01 Mar 2021
Thesis: In silico repositioning of FDA-approved drugs as inhibitors of Porphyromonas gingivalis peptidylarginine deiminase, a putative causal agent of rheumatoid arthritis
a
Natasha Stella Tibon | Undergraduate | 03 Dec 2018 - 28 Feb 2019
Thesis: Literature review: Multi-target approaches in malaria drug discovery
a
Chai Shin Yiing, Corina Sia Yao Lian, Chen Kee Zhe, Woo Yi Mun | Undergraduate | 01 Jul 2018 - 01 Nov 2018
Thesis: Synthesis of Novel Bis (Indolymethyl) Carbazoles
a
Ngew Wei Yue, Chan Kuan Hui | Undergraduate | 01 Jun 2018 - 01 Dec 2018
Thesis: Synthesis, Characterisation and Antimicrobial (In vitro and In Silico) Evaluation of Schiff Base Ligands and their Metal Complexes
a
Chuah Chong Ho, Tong Jin Yan, Chia Jing Wen | Undergraduate | 01 Dec 2015 - 29 Feb 2016
Thesis: Effect of some organic and inorganic proteasome inhibitors on the growth of selected bacteria
a
Jong Yi Wen, Joyce Wong Xin Yi | Undergraduate | 01 May 2015 - 31 Oct 2015
Thesis: Bicyclic scaffold as versatile template for the design of human adenosine receptor antagonists: Comparison of pharmacophore elucidation at the A2A and A3 adenosine receptor.